Media OutReach
Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone
“Driving the Globalization of Clinical Trials in the Guangdong-Hong Kong-Macao Greater Bay Area, Implementing the First Key Cross-Border Multi-Center Clinical Trial Project”
HONG KONG SAR – Media OutReach Newswire – 30 July 2025 – The Greater Bay Area International Clinical Trial Institute of Hong Kong (“GBAICTI“), the Greater Bay Area International Clinical Trials Center of Shenzhen (“BAY TRIAL“), Immuno Cure BioTech (“Immuno Cure“) in Hong Kong are pleased to jointly announce today the signing of a tripartite Memorandum of Understanding (“MOU“) in Shenzhen on July 29, 2025. This collaboration aims to advance the globalization of clinical trials in the Guangdong-Hong Kong-Macau Greater Bay Area (“GBA“), further deepens clinical research cooperation between Hong Kong and Shenzhen, and implements the first ever cross-border multi-centre Phase II clinical trial project for ICVAX, a therapeutic DNA vaccine for HIV/AIDS, developed through collaboration between Immuno Cure and the AIDS Institute at the University of Hong Kong. This marks a significant milestone in the development of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone.
This collaboration is witnessed by a Hong Kong Government delegation led by the Director of Health, Dr. Ronald LAM, and a Shenzhen Government delegation led by the Deputy Director General of Public Hygiene and Health Commission of Shenzhen Municipality, Ms. ZHOU Liping, following their GBA Clinical Trial Collaboration meeting held in Shenzhen.
GBAICTI and the BAY TRIAL plan to establish the GBA Clinical Trial Collaboration Platform (“Platform“) by the end of this year. The Platform is expected to offer a range of services, including project evaluation, trial design consultation, and subject recruitment planning for multi-centre clinical trials, provided by a joint Shenzhen-Hong Kong advisory team; integration of artificial intelligence technologies to assist with matching clinical trial institutions and researchers, as well as offering intelligent consultation services; establishment of a coordinated ethics review mechanism between the two regions to enhance approval efficiency; promotion of talent exchange, collaboration, and professional training; creation of a research talent pool to facilitate talent mobility and regional collaboration; and as a pilot, the development of clinical databases and biobanks based on disease areas of strength in both Shenzhen and Hong Kong.
Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI, said: “The ICVAX vaccine, developed by Immuno Cure and the AIDS Institute at the University of Hong Kong, is now poised for cross-border clinical trials in the Greater Bay Area. This highlights the achievements and potential of innovation and technology in China and the Hong Kong SAR. If the clinical trial results are positive, the new vaccine would bring hope to HIV/AIDS patients worldwide, particularly in Belt and Road countries. We aim to leverage the strength of both Guangdong and Hong Kong to establish the Guangdong-Hong Kong-Macao Greater Bay Area as a global hub for clinical trials.”
Dr. LI Yichong, Director of BAY TRIAL, said: “This collaboration marks the first cross border clinical trial project between the BAY TRIAL and Hong Kong, signifying a new phase in the cooperation between Shenzhen and Hong Kong in the biopharmaceutical sector of GBA. We will fully leverage the synergistic advantages of both regions to establish an international clinical trial platform with the BAY TRIAL, continuously injecting new momentum into the high-quality development of the Bay Area’s pharmaceutical and medical device industry.”
Since the first discovery of AIDS in 1981, 40 million people have died from HIV infection. Currently, there are still over 39 million people living with HIV worldwide. Although antiretroviral therapy (“ART“) can effectively control HIV, it cannot cure the disease, highlighting the importance of immunotherapy. Immunotherapy aims to enhance the host’s immune response, with the expectation of controlling viral replication without ART, ultimately achieving complete viral suppression and functional cure. Immuno Cure’s ICVAX induces broad-spectrum, multifunctional virus-specific T cells to achieve the goal of controlling viral replication without ART.
Immuno Cure completed the first-in-human Phase I clinical trial of the ICVAX vaccine in November 2024. The results demonstrated excellent safety and good immunogenicity. This year, two multi-center Phase II clinical trials will be conducted to evaluate the mechanism of action and efficacy, respectively, of ICVAX in humans. Both are randomized, double-blind, placebo-controlled, dose-escalation studies, with clinical trial centres in the Prince of Wales Hospital in Hong Kong and eight Grade 3A hospitals in China, including The Third People’s Hospital of Shenzhen, Beijing Ditan Hospital, Beijing Youan Hospital, Guangzhou Eighth People’s Hospital, Tianjin Second People’s Hospital, The Sixth People’s Hospital of Zhengzhou, Chengdu Public Health Clinical Medical Center, and Chongqing Public Health Medical Center.
Dr. Xia JIN, Chief Executive Officer of Immuno Cure, said: “We are delighted to receive support from both GBAICTI and BAY TRIAL, integrating medical resources from both regions to advance Immuno Cure’s therapeutic vaccine for HIV, ICVAX, to multi-center Phase II clinical trials. We will continue to collaborate with the HKU AIDS Institute to drive innovation in drug development, leverage local advantages in drug research and translation, accelerate ICVAX towards commercialization, provide more effective treatment options for HIV patients, and contribute to global health.”
GBAICTI, BAY TRIAL, and Immuno Cure look forward to further deepening clinical trial cooperation between Shenzhen and Hong Kong in future collaborations, jointly promoting the development and globalisation of innovative drug development, and supporting the national “Healthy China” strategic goals.
Hashtag: #ImmunoCure #醫克生物 #医克生物
https://www.immunocure.hk/
https://www.linkedin.com/company/immuno-cure/
The issuer is solely responsible for the content of this announcement.
About GBAICTI
The Greater Bay Area International Clinical Trial Institute (GBAICTI) is located in the Hong Kong Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Co-operation Zone. Its mission is to coordinate public and private medical resources in Hong Kong, providing a one-stop support platform for research institutions. This aims to promote process optimization, talent training, and collaboration within the Greater Bay Area, accelerating the research and development of drugs and medical devices, allowing research outcomes to benefit patients more quickly. By closely collaborating with the Greater Bay Area International Clinical Trials Center, it leverages the unique advantages of “one institute, one center” to jointly coordinate cross-border, multi-center clinical trials that meet international standards.
To learn more about GBAICTI, please visit:
https://gbaicti.hk/
About BAY TRIAL
The Greater Bay Area International Clinical Trials Center (BAY TRIAL) is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform. This platform provides top-tier clinical trial technical support, operational management, and registration services for domestic and international pharmaceutical and medical device R&D institutions. Additionally, BAY TRIAL will act as a “testing ground” for clinical trial regulation reforms and a “catalyst” for technological innovation, facilitating the alignment of clinical trial regulations and standards with international benchmarks, promoting the development and application of cutting-edge trial technologies, building a collaborative medical technology innovation network in the GBA, and enhancing the region’s competitiveness in the pharmaceutical and medical device industry.
To learn more about BAY TRIAL, please visit:
https://baytrial.smart.org.cn/about/index.html
About Immuno Cure
Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine, Anti-Δ42PD1 Antibody; and Vaccine Delivery platforms.
To learn more about Immuno Cure, please visit:
www.immunocure.hk
Media OutReach
SIM Introduces CareerSense, an AI-Based Career Guidance Platform for Students
CareerSense Matters in Today’s Job Market
The global workforce is evolving rapidly. Automation, digitalisation, and emerging technologies are creating new opportunities while presenting new challenges. Navigating this landscape requires more than academic credentials; it demands self-awareness, adaptability, and strategic planning.
CareerSense addresses these needs by combining artificial intelligence with career development expertise, offering a personalised, data-driven approach to job readiness. It functions as a comprehensive career coach, accessible anytime and anywhere.
Key Features That Set CareerSense Apart
CareerSense offers a comprehensive suite of features designed to empower students throughout their career journey. Its AI-driven VIPS profiling evaluates Values, Interests, Personality, and Skills to deliver personalised career recommendations aligned with individual strengths and aspirations. The smart resume builder provides real-time scoring and improvement tips, while the job-matching algorithm connects students to roles that fit their unique profiles. Through integrated access, students can RSVP for events, schedule advisory sessions, and apply for internships and job listings seamlessly. Additionally, the Employability Index measures job readiness and works alongside skill gap analysis and tailored course recommendations to help students stay competitive in today’s dynamic job market.
The Bigger Picture: Empowering Future-Ready Graduates
The future of work is shaped by constant change, technological disruption, and global connectivity. Employers seek individuals who are adaptable, self-aware, and equipped with relevant skills. CareerSense empowers students to take ownership of their career journey, understand their strengths, identify gaps, and build competencies that matter in the real world.
This initiative reflects SIM’s commitment to lifelong learning and employability, ensuring graduates are not only job-ready but future-ready. In a competitive market, CareerSense positions SIM learners as confident, agile professionals prepared to lead in the digital economy.
References:
- Introducing CareerSense: Your All-in-One Personalised Career Buddy On-The-Go – https://www.sim.edu.sg/articles-inspirations/introducing-careersense-your-all-in-one-personalised-career-buddy-on-the-go
- Career Service – https://www.sim.edu.sg/degrees-diplomas/life-at-sim/career-services
- SIM Career Sense App (Google Play Store) – https://play.google.com/store/apps/details?id=sg.edu.sim.careersense&hl=en-US&pli=1
- SIM Career Sense App (Apple Store) – https://apps.apple.com/sg/app/sim-careersense/id1641839680
- Introducing CareerSense: Your Guide to Career Success After Graduation – https://regional.simge.edu.sg/en/introducing-careersense-your-guide-to-career-success-after-graduation/
Hashtag: #SIMGlobalEducation #SIMGE #GlobalEducation #InternationalDegree #CareerReady #FutureSkills
The issuer is solely responsible for the content of this announcement.
About SIM Global Education
SIM Global Education (SIM GE) is a leading private education institution in Singapore and the region. We offer more than 140 academic programmes ranging from diplomas and graduate diploma programmes to bachelor’s and master’s degree programmes with some of the world’s most reputable universities from Australia, Canada, Europe, United Kingdom, and the United States. SIM GE’s cohort is made up of 16,000 full- and part-time students and adult learners, of which approximately 36% are international students hailing from over 50 countries.
SIM GE’s holistic learning approach and culturally diverse learning environment aim to equip students with knowledge, industry skills and employability competencies, as well as a global perspective to succeed as future leaders in a fast-changing, technologically driven world.
For more information on SIM Global Education, visit sim.edu.sg
Media OutReach
TVB ESG Awards 2025 Presentation Ceremony
Hong Kong and Macau Organisations Honoured for Outstanding Achievements ESG-led Business for a Sustainable Future
HONG KONG SAR – Media OutReach Newswire – 19 December 2025 – With global acceleration towards sustainable development and rising expectations from investors and stakeholders for responsible business practices, Hong Kong and Macau enterprises in recent years have been actively integrating Environmental, Social and Governance (ESG) vision into their business strategies to drive green transformation and high-quality growth. Organised by Television Broadcasts Limited (TVB) and co-organised by the Hong Kong Productivity Council, the TVB ESG Awards 2025 (the Awards) aim to recognise and commend enterprises and organisations that have demonstrated outstanding performance in ESG and sustainable development. Now in its fourth edition, this annual flagship event recognise outstanding organisations and their achievements in ESG practices over the past year.
The ceremony was officiated by Mr. Michael WONG, GBS, JP, Deputy Financial Secretary; Dr. LAM Ching-choi, GBS, JP, Non-official Member of the Executive Council & Chairman of the Council for Carbon Neutrality & Sustainable Development; Mr. SIU Sai Wo, General Manager (Business Operations), Television Broadcasts Limited; and Dr. Lawrence CHEUNG Chi-chong, Chief Technology Officer, Hong Kong Productivity Council. Following the Green Summit held in July this year, the presentation ceremony also featured sharing sessions, inviting industry leaders and experts to exchange the latest trends and practical experience. In addition, the enhanced matching sessions enabled enterprises to connect with numerous attendees through exhibition booths to promote cross-sector collaboration and knowledge sharing.
Diverse Award Categories Recognise ESG Efforts of Hong Kong and Macau Industries
This year’s Awards include the “Outstanding ESG Award”, “Best in ESG Practices”, “Best in ESG Report”, “ESG Environmental Innovative Technology Award” and “ESG Social Innovative Technology Award”. Entries were open to five groups, namely large, medium, small market capitalisation/ GEM listed companies, as well as non-listed companies and non-profit organisations, to recognise the achievements of enterprises of different scales in ESG practices, reporting and innovation. To identify outstanding performers, a cross-sector professional judging panel appointed by TVB were responsible for assessing entries, using clear and diversified selection criteria that mainly cover five areas: environment, social, corporate governance, sustainability strategy, corporate information disclosure and communication.
Additionally, a new “Greater Bay Area ESG Excellence Enterprise Award (Macau SAR)” has been introduced this year to recognise Macau enterprises and organisations with outstanding ESG performance that actively promote sustainable development in the Macau community. Furthermore, to enhance and recognise the excellent performance of small and medium-sized enterprises (SMEs) in ESG practices and innovation, TVB has collaborated with the “ESG One” platform of the Hong Kong Productivity Council to launch the “SME ESG Excellence Award” this year. The award covers five areas: “Business Decarbonisation”, “Employee Care”, “Supply Chain Partnership”, “Sustainable Governance” and “ESG Technology Enhancement”, helping SMEs to progressively enhance their ESG performance. Organisations that did not receive the above ESG category awards but have actively performed and implemented ESG initiatives in various aspects will be eligible for nomination of “ESG Special Recognition Award – with Merit” or “ESG Special Recognition Award” in acknowledgement of their contributions.
Mr. Michael WONG, GBS, JP, Deputy Financial Secretary, said in his keynote speech, “Hong Kong possesses significant advantages in green economy transformation. As the city’s two major innovation and technology flagships, Hong Kong Science Park and Cyberport have now brought together over 270 green technology companies, representing growth of more than 80% compared to 2023, reflecting remarkably rapid development in recent years. Hong Kong can provide diversified investment and financing channels, enabling international capital to match with quality green projects. As of the end of September this year, there are over 200 SFC-authorised ESG funds with assets under management exceeding HKD1.1 trillion, demonstrating that investors are increasingly prioritising investment in sustainable development. The Government looks forward to continued collaboration with all of you to jointly build our sustainable future and make outstanding contributions to Hong Kong’s green economic development.”
Mr. SIU Sai Wo, General Manager (Business Operations), Television Broadcasts Limited, said, “The TVB ESG Awards 2025 received over 250 corporate entries this year, reflecting the growing importance of ESG for enterprises. We are grateful to all award-winning organisations and partners for their continued support of this flagship award. This year’s awardees excelled in ESG performance and set forward-looking models for the industry. TVB is actively supporting enterprises to devote resources to ESG development, incorporate sustainability into business decision-making and operations, and strengthen their sense of social responsibility. The Awards also provide a professional exchange platform for enterprises of different industries and scales to share their ESG strategies and tangible outcomes with a wider range of stakeholders.”
To help the public gain a more comprehensive understanding of the vision, mission and innovative strategies of various enterprises, the presentation ceremony featured sharing sessions. The judge Dr. Lawrence CHEUNG Chi-chong, Chief Technology Officer, Hong Kong Productivity Council, together with representatives from enterprises receiving the Outstanding ESG Award, exchanged practical insights. As the highest honour of this year’s Awards, the Outstanding ESG Award is conferred upon top-tier organisations in each category that have achieved the best performance in both “ESG Practices” and “ESG Report”. The award-winning enterprises shared their insights in the session titled “Partnering Across Sectors to Co-create a Low-carbon Future”:
- Ms. Jessica CHAN, Head of Sustainability of MTR Corporation, shared how MTR leverages its diversified business portfolio to drive carbon reduction and social inclusion in daily operations, thus encouraging business partners to enhance their ESG performance.
- Ms. Angel SZE, Company Secretary and Head of ESG Management Committee, Fosun International Limited, who shared how Fosun is driving innovation and global development to create value, while highlighting effective ESG practices for cross‑industry and cross‑regional enterprises.
- Ms. Connie LAU, Assistant General Manager, Legal Department, China State Construction Development Holdings Limited, who used examples of innovative applications to demonstrate the company’s breakthroughs and decarbonisation goals.
- Mr. Jonathan CHIU, President, Schneider Electric Hong Kong, who highlighted the company’s commitment as a global energy technology leader to driving efficiency and sustainability by electrifying, automating and digitalising industries, businesses and homes, contributing to Hong Kong’s low-carbon transition.
- Mr. Peter LEE, Chief Sustainability Officer, Airport Authority Hong Kong, elaborated on how the authority collaborates with business partners and extends the sustainability concept to the society and education sector.
- Mr. Oswald AU, Managing Director, Riskory Consultancy Limited, shared how SMEs can drive ESG through innovative solutions and practical actions, while leveraging mega event economy development to create greater impact.

Building on these insights, another sharing session titled “Building a Green and Sustainable Pathway: Advancing Liveable, Inclusive Smart Cities” invited Mr. Andy WONG, Senior Manager, Advocacy, Our Hong Kong Foundation, as moderator. He was joined by Ir. Franco CHEUNG, Director (Projects), Hong Kong Housing Society, Mr. Samuel KWONG, Senior Associate Director – ESG, Chinachem Group and Mr. Jeffery LOK, Managing Director, Kwan On Chemical Enterprise Co. Ltd., for in-depth discussions on topics such as decarbonisation planning, the application of green building technologies including Modular Integrated Construction (MiC), kitchen and grease trap waste oil recycling, exploring the roadmap for Hong Kong and Macau’s sustainable urban development and environmental benefits.

Strong Corporate Involvement Fosters Cross-Sector Connections
This year’s ceremony attracted enthusiastic participation from numerous enterprises and organisations, including listed companies, non-listed companies and non-profit organisations, signalling the local market’s increasing commitment to ESG. Enhanced matching sessions with exhibition booths were arranged before and after the ceremony, allowing participants to engage in in-depth exchanges on green technology solutions, sustainable development and eco-friendly materials, and to explore collaboration opportunities.
For the full list of award winners, please visit: https://www.tvbesg.com.hk/past-awards/esg-awards-2025
High resolution photos HERE
Hashtag: #TVBESGAwards #TVB #ESG #Corporate
The issuer is solely responsible for the content of this announcement.
About TVB ESG
Since 2022, TVB ESG has been committed to building a professional exchange platform for local sustainable development, promoting a deeper understanding, implementation, and strategic development of Environmental, Social and Governance (ESG) issues among businesses and different sectors of society. TVB ESG works closely with various organisations to foster cross-sector collaboration, help enterprises expand their professional networks and strengthen industry connections, while enhancing their visibility in the market and industry through diverse channels, thereby amplifying their impact in the ESG field.
To enhance industry exchange and promote a culture of sustainability, TVB ESG organises three core events every year, the Green Forum, the Green Summit and the “TVB ESG Awards”. These events aim to focus on key environmental issues and emerging trends, bringing together industry leaders and experts to provide forward-looking insights for enterprises, promote knowledge sharing, and facilitate the exchange of best practices. Through the “TVB ESG Awards”, TVB ESG also recognises enterprises and organisations with outstanding achievements in sustainable development, encouraging the industry to continuously implement and elevate ESG standards.
Media OutReach
2025 Annual Claims Data Report: Bridging Information Gaps with Full Disclosure
1. Work Injury Claims Data (Total: 1,032 Cases)
Sick Leave Distribution:
- 0 – 30 Days: 279 cases
- 31 – 100 Days: 323 cases
- 101 – 300 Days: 261 cases
- 301 – 700 Days: 145 cases
- 701 – 1,000 Days: 18 cases
- 1,001 – 2,000 Days: 3 cases
- Over 2,000 Days: 3 cases
Summary: Over 58% of cases involve fewer than 100 days of sick leave, indicating that minor injuries remain the norm. However, extreme cases exceeding 2,000 days highlight the dire need for long-term legal and financial support for severely injured workers.
Assessment of Earning Capacity:
- 0% – 4%: 745 cases
- 5% – 14%: 188 cases
- 15% – 34%: 52 cases
- 35% – 64%: 11 cases
- 65% – 94%: 10 cases
- 95% – 100%: 26 cases
Summary: A “pyramid” distribution is observed, with 72% involving minor impairments. Yet, the 26 cases of near-total disability (95-100%) underscore the catastrophic impact of high-risk workplace accidents on families.
Estimated Results:
- HK$0 – $50,000: 381 cases
- HK$50,001 – $100,000: 226 cases
- HK$100,001 – $200,000: 147 cases
- HK$200,001 – $500,000: 109 cases
- HK$500,001 – $1,000,000: 125 cases
- HK$1,000,001 – $2,000,000: 31 cases
- HK$2,000,001 – $5,000,000: 13 cases
Summary: 16% of inquiries yield estimates above HK$500,000. These cases often involve complex future loss of earnings, signaling a high demand for specialized legal advocacy in high-value claims.
2. Traffic Accident Claims Data (Total: 868 Cases)
Injured Body Parts:
- Back / Spine: 176 cases
- Lower Back / Hips: 118 cases
- Head: 112 cases
- Shoulder: 111 cases
- Neck: 105 cases
- Leg: 104 cases
- Knee: 74 cases
- Arm: 68 cases
Summary: Back and spine injuries are the most frequent, often resulting from whiplash in rear-end collisions. These injuries are critical for PSLA (Pain, Suffering, and Loss of Amenities) evaluations in civil court.
Nature of Injuries:
- Sprain: 241 cases
- Fracture: 180 cases
- Contusion: 169 cases
- Nerve / Brain: 139 cases
- Internal: 74 cases
- Dislocation: 65 cases
Summary: While sprains are most common, the high number of nerve and brain injuries (139 cases) is concerning, as these often lead to permanent functional impairment.
Estimated Results:
- HK$0 – $100,000: 422 cases
- HK$100,001 – $200,000: 162 cases
- HK$200,001 – $500,000: 179 cases
- HK$500,001 – $1,000,000: 98 cases
- HK$1,000,001 – $2,000,000: 5 cases
- HK$2,000,001 – $10,000,000: 0 cases
- Over HK$10,000,000: 2 cases
Summary: Traffic claims show extreme polarization. While most stay below HK
$100k, two cases exceeded HK$ 10 million, reflecting the massive social cost of life-altering road collisions.
Mandatory Disclaimer
IMPORTANT: All compensation figures are generated by the “AI Compensation Calculator” based on user input. These are preliminary estimates only and not final actual compensation amounts. Final payouts depend on court rulings, liability apportionment, and medical evidence. Victims must seek formal legal advice from practicing lawyers.
Hashtag: #HKAccidentLawyers #HKCivilClaim #PersonalInjury #WorkInjury #CivilClaims #ClaimsData
The issuer is solely responsible for the content of this announcement.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism9 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking7 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn











